CAR T-Cell Therapy Evolves in Leukemia Treatment Landscape
July 14, 2020 • AML Content Hub
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in leukemias. Park says CAR T-cell therapy still has limitations and challenges that need to be addressed. Notably, Park cites durable responses as the overall marker needed to make CAR T-cell therapy a viable and definitive treatment option. Click here to learn more.
